
    
      Subjects With fatty liver are given Hepaxa for 6 months. Fibroscan CAP measurements are taken
      at 3 monthly intervals. Subjects consent to Collection of data from approximately 6 months
      prior to use of Hepaxa. Patients unresponsive to life style recommendations given as standard
      practice will be enrolled.
    
  